Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Sep 21, 2024; 30(35): 3996-4010
Published online Sep 21, 2024. doi: 10.3748/wjg.v30.i35.3996
Table 1 Patient characteristics at baseline, n (%)
Characteristic
All (n = 255)
Age (years), mean ± SD40.2 ± 8.9
Sex
        Male195 (76.5)
        Female60 (23.5)
BMI (kg/m2), mean ± SD26.7 ± 3.9
History of hypertension42 (16.5)
History of diabetes60 (23.5)
Pleural effusion129 (50.6)
Peritoneal effusion78 (30.6)
Localized complications183 (71.8)
APFC62 (24.3)
ANC93 (36.5)
PPC17 (6.7)
WON3 (1.2)
IPN8 (3.1)
Systemic complications135 (52.9)
Respiratory failure53 (20.8)
Renal failure39 (15.3)
Circulatory failure16 (6.3)
SIRS123 (48.2)
Sepsis17 (6.7)
ACS22 (8.6)
ARDS16 (6.3)
MODS32 (12.5)
Grades of severity
        MAP72 (28.2)
        MSAP126 (49.4)
        SAP57 (22.4)
ICU admission54 (21.2)
Length of hospital stays (days), median (IQR)10 (6, 14)
Total costs (thousand CNY), median (IQR)19.7 (11.0, 37.8)
Mortality2 (0.78)
Table 2 Impact of individual metabolic syndrome components on adverse clinical outcomes in hypertriglyceridemia-acute pancreatitis
OutcomeObesity
Hyperglycaemia
Hypertension
Low HDL-C
OR (95%CI)
P value
OR (95%CI)
P value
OR (95%CI)
P value
OR (95%CI)
P value
Pleural effusion1.52 (0.89-2.61)0.1291.75 (0.88-3.46)0.1091.12 (0.69-1.84)0.6442.57 (1.55-4.27)< 0.001a
Peritoneal effusion0.98 (0.55-1.75)0.9411.44 (0.67-3.11)0.3491.20 (0.70-2.05)0.5053.02 (1.70-5.36)< 0.001a
Localized complications2.07 (1.07-4.00)0.031a3.04 (1.53-6.06)0.002a0.82 (0.47-1.42)0.4762.06 (1.18-3.59)0.011a
APFC2.73 (1.50-4.96)0.001a2.61 (0.98-6.99)0.0550.96 (0.54-1.71)0.8890.82 (0.46-1.46)0.499
ANC1.02 (0.59-1.79)0.9631.47 (0.71-3.05)0.2980.75 (0.45-1.25)0.2712.32 (1.37-3.94)0.002a
PPC0.48 (0.13-1.74)0.4840.89 (0.24-3.24)0.8551.45 (0.54-3.89)0.4610.58 (0.21-1.58)0.288
Systemic complications1.81 (1.05-3.14)0.034a2.86 (1.40-5.82)0.004a1.81 (1.09-2.98)0.021a2.38 (1.43-3.93)0.001a
Respiratory failure2.16 (1.15-4.04)0.016a2.08 (0.77-5.60)0.1461.40 (0.76-2.57)0.2764.94 (2.35-10.37)< 0.001a
Renal failure2.06 (1.02-4.14)0.044a2.56 (0.75-8.75)0.1330.85 (0.43-1.71)0.6543.40 (1.54-7.49)0.002a
Circulatory failure1.08 (0.36-3.21)0.8963.02 (0.39-23.48)0.2920.55 (0.19-1.64)0.2832.74 (0.86-8.73)0.089
SIRS1.39 (0.81-2.37)0.2353.04 (1.53-6.06)0.002a1.84 (1.12-3.03)0.0171.76 (1.07-2.90)0.026a
Sepsis0.71 (0.22-2.25)0.5601.47 (0.32-6.69)0.6181.13 (0.42-3.02)0.8142.99 (0.95-9.43)0.062
ACS1.11 (0.43-2.84)0.8291.23 (0.35-4.38)0.7451.57 (0.65-3.78)0.3152.47 (0.93-6.53)0.069
ARDS1.92 (0.69-5.35)0.2141.37 (0.30-6.25)0.6881.28 (0.46-3.51)0.6374.02 (1.12-14.47)0.033a
MODS1.74 (0.81-3.73)0.1563.18 (0.73-13.86)0.1240.84 (0.40-1.79)0.6543.54 (1.47-8.52)0.005a
SAP1.85 (1.00-3.43)0.0501.83 (0.73-4.59)0.2011.17 (0.65-2.12)0.5984.32 (2.16-8.66)< 0.001a
ICU admission1.69 (0.90-3.17)0.1022.14 (0.80-5.74)0.1321.47 (0.80-2.69)0.2113.91 (1.94-7.85)< 0.001a
Table 3 Association of metabolic syndrome component count with clinical severity scores and hospitalization characteristics in hypertriglyceridemia-acute pancreatitis, n (%)
CharacteristicNumber of metabolic syndrome components
P value
1 (n = 6)
2 (n = 61)
3 (n = 102)
4 (n = 69)
5 (n = 17)
Age (years)35.8 ± 8.839.8 ± 9.640.9 ± 8.239.5 ± 9.940.2 ± 8.90.545
Sex
        Male5 (2.6)42 (21.5)76 (39.0)57 (29.2)15 (7.7)0.290
        Female1 (1.7)19 (31.7)26 (43.3)12 (20.0)2 (3.3)
Scoring systems
Ranson0.5 (0, 1)1 (1, 3)2 (1, 3)2 (1, 4)4 (2, 5)< 0.001a
BISAP0 (0, 0.5)0 (0, 1)1 (0, 2)2 (1, 2)2 (1, 2.5)< 0.001a
MCTSI4 (2, 6.5)4 (2, 8)6 (2, 8)8 (4, 8)8 (4, 8)0.005a
Length of hospital stays (days)6 (4.3, 9.8)8 (5, 12.5)10 (7, 14.3)11 (6, 17)19 (13, 19.5)0.014a
Total costs (thousand CNY)8.6 (5.9, 17.1)14.0 (6.8, 24.6)17.9 (11.4, 37.7)26.1 (14.7, 61.1)25.8 (16.7, 81.3)< 0.001a
Table 4 Relationship between metabolic syndrome and clinical outcomes in hypertriglyceridemia-acute pancreatitis
Outcome parameterGroup
Non-metabolic syndrome
Low-component metabolic Syndrome
High-component metabolic syndrome
OR (95%CI)
P value
OR (95%CI)
P value
OR (95%CI)
P value
Pleural effusionReference-2.16 (1.13-4.14)0.019a3.43 (1.73-6.80)< 0.001a
Peritoneal effusionReference-2.27 (1.04-4.92)0.039a3.78 (1.72-8.34)0.001a
Localized complicationsReference-2.14 (1.11-4.13)0.023a3.63 (1.73-7.65)0.001a
APFCReference-1.61 (0.73-3.55)0.2402.09 (0.94-4.65)0.071
ANCReference-0.99 (0.52-1.93)0.9921.64 (0.84-3.20)0.149
PPCReference-1.10 (0.33-3.62)0.8760.72 (0.18-2.89)0.638
Systemic complicationsReference-2.67 (1.38-5.16)0.004a6.49 (3.17-13.30)< 0.001a
Respiratory failureReference-3.24 (1.03-10.16)0.044a9.32 (3.07-28.25)< 0.001a
Renal failureReference-1.54 (0.55-4.30)0.4143.02 (1.12-8.11)0.028a
Circulatory failureReference-2.86 (0.56-14.73)0.2073.14 (0.60-16.26)0.173
SIRSReference2.54 (1.30-4.93)0.006a4.54 (2.25-9.14)< 0.001a
SAPReference-1.88 (0.74-4.82)0.1875.05 (2.04-12.49)< 0.001a
ICU admissionReference-2.25 (0.83-6.13)0.1126.41 (2.42-16.97)< 0.001a